{"title":"萎缩性胃炎和肠化生作为胃癌前病变的认识现状","authors":"Zornica Gorcheva","doi":"10.2478/jbcr-2022-0016","DOIUrl":null,"url":null,"abstract":"Summary Gastric cancer is the fifth most common and third leading cause of cancer death worldwide. Patients with chronic atrophic gastritis (CAG) and intestinal metaplasia (IM) are at increased risk of developing gastric cancer (GC). It is common for CAG to precede IM, but the etiology of the two conditions is not always the same. Different scoring systems are used to assess HAG, MI, and GC risk, making it difficult to interpret results from investigations and management of these conditions.","PeriodicalId":15099,"journal":{"name":"Journal of Biomedical and Clinical Research","volume":"21 1","pages":"118 - 122"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Current Understanding of Atrophic Gastritis and Intestinal Metaplasia as a Premalignant Lesion of Gastric Cancer\",\"authors\":\"Zornica Gorcheva\",\"doi\":\"10.2478/jbcr-2022-0016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Summary Gastric cancer is the fifth most common and third leading cause of cancer death worldwide. Patients with chronic atrophic gastritis (CAG) and intestinal metaplasia (IM) are at increased risk of developing gastric cancer (GC). It is common for CAG to precede IM, but the etiology of the two conditions is not always the same. Different scoring systems are used to assess HAG, MI, and GC risk, making it difficult to interpret results from investigations and management of these conditions.\",\"PeriodicalId\":15099,\"journal\":{\"name\":\"Journal of Biomedical and Clinical Research\",\"volume\":\"21 1\",\"pages\":\"118 - 122\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biomedical and Clinical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2478/jbcr-2022-0016\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biomedical and Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/jbcr-2022-0016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Current Understanding of Atrophic Gastritis and Intestinal Metaplasia as a Premalignant Lesion of Gastric Cancer
Summary Gastric cancer is the fifth most common and third leading cause of cancer death worldwide. Patients with chronic atrophic gastritis (CAG) and intestinal metaplasia (IM) are at increased risk of developing gastric cancer (GC). It is common for CAG to precede IM, but the etiology of the two conditions is not always the same. Different scoring systems are used to assess HAG, MI, and GC risk, making it difficult to interpret results from investigations and management of these conditions.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
